Baird analyst Joel Beatty raised the firm’s price target on Immutep (IMMP) to $7 from $6 and keeps an Outperform rating on the shares. The firm raised its target after the company announced investigator initiated INSIGHT-003 study data today for their lead agent eftilagimod alpha (efti).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMP: